Ken is our President and Chief Executive Officer and a member of our board of directors. He has more than 10 years’ experience developing and building companies in the life sciences and the diagnostic industry. Prior to joining Metacrine, he was the Chief Executive Officer of Ariosa Diagnostics, Inc., a DNA molecular diagnostics company. Before that he was a Vice President at Venrock, a venture capital firm, leading investments in private and public healthcare companies. Previously, Ken trained as both an internist and gastroenterologist and conducted translational and clinical outcome research at the University of California, San Francisco, University of Washington and the Fred Hutchinson Cancer Center. He started his business career as a consultant at McKinsey. Ken also serves as Executive Chairman of Omniome, a DNA sequencing company. He holds a B.S. in biology from the Massachusetts Institute of Technology and an M.D. from the University of California, San Francisco.
Amir has served as a member of our board of directors since January 2015. He is a managing partner at Polaris Partners, a venture capital firm, where he has worked since April 2002. Amir was also the founding Chief Executive Officer of Living Proof, Inc. and Sun Catalytix Corporation. He currently represents Polaris on the boards of Scholar Rock, Agbiome, Inc., aTyr Pharmaceuticals, Inc., Fate Therapeutics, Inc., Jnana Therapeutics, where he also serves as the Chief Executive Officer, CAMP4, Morphic Therapeutic, Inc., Olivo Labs, Promedior, Inc., Selecta Biosciences Inc., Syros Pharmaceuticals, Inc., and Taris Biomedical, LLC. Amir also serves on the Partners Innovation Fund, the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president. He previously served on the board of directors of the New England Venture Capital Association. Amir received an M.S. and B.S. in materials science and mechanical engineering from the University of California, Berkeley and a Sc.D. as a Hertz Fellow in chemical engineering at MIT with a minor in biology.
Andrew has served as a member of our board since July 2018. He currently serves as Chief Financial Officer of Dermira, Inc., a public biopharmaceutical company focused on medical dermatology. Previously, Andrew served as Chief Financial Officer of CardioDx, Inc., a molecular diagnostics life sciences company, from September 2011 to April 2014, and as a member of the CardioDx board of directors from April 2014 until July 2016. From September 2010 to April 2011, he served as Chief Financial Officer of Calistoga Pharmaceuticals, Inc., a biotechnology company acquired in April 2011 by Gilead Sciences, Inc. From December 2008 to June 2010, Andrew served as Senior Vice President and Chief Financial Officer of Facet Biotech Corporation. Facet Biotech Corporation was spun off from PDL BioPharma, Inc. where he served as Senior Vice President and Chief Financial Officer from April 2006 to December 2008. From October 2000 to March 2006, Andrew served as Chief Financial Officer of Neoforma, Inc., a provider of supply-chain management solutions for the healthcare industry. From January to October 2000, he served as Neoforma’s Vice President, Corporate Development. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He holds a B.A. in International Politics and Economics from Middlebury College and holds an MBA. from the J.L. Kellogg Graduate School of Management at Northwestern University.
Carol has served as a member of our board of directors since November 2017. Since October 2014, she has served as a partner with New Enterprise Associates, a venture capital firm. Prior to joining New Enterprise Associates, Carol served as a venture partner with Frazier Healthcare from October 2013 to September 2014. She served as the President and Chief Executive Officer of Calistoga Pharmaceuticals, Inc., a biopharmaceutical company, from 2008 to 2011, when the company was acquired by Gilead Sciences. From 2007 to 2008, Carol was the President and Chief Executive Officer of Metastatix, Inc., a biopharmaceutical company. Between 1989 to 2007, she served in various roles at pharmaceutical companies Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Biogen Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. Carol attended Vanderbilt University and received B.S. and Doctor of Pharmacy degrees from the University of Kentucky
Ronald, one of our co-founders, has served as a member of our board of directors since September 2014. He is a professor, director and biologist at The Salk Institute, where he serves as the March of Dimes Chair in Molecular and Developmental Neurobiology. Ronald became a faculty member of The Salk Institute in 1978. He also serves as a Howard Hughes Medical Institute Investigator, a position he has held since 1985. Ronald was elected to the National Academy of Sciences in 1989. He received his B.S. and Ph.D. degrees from UCLA in 1970 and 1974, respectively, followed by a postdoctoral training at Rockefeller University from 1975-1978.
Kristina has served as a member of our board of directors since May 2015. She has served as Managing Director of ARCH Venture Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Kristina currently serves on the board of several biopharmaceutical and biotechnology companies, including Scholar Rock Holding Corporation, Vividion, Beam Therapeutics, Lycera Corp., BlackThorn Therapeutics, Inc., Sienna Biopharmaceuticals, Inc., Unity Biotechnology, Inc., AgBiome Inc., Vir Biotechnology Inc. and Gossamer Bio, Inc. She previously was a co-founder and member of the board of directors of Receptos Inc., until its acquisition by Celgene Corporation, and of Sapphire Energy, Inc., an energy company. Kristina has participated in a number of other ARCH portfolio companies including KYTHERA, Siluria Technologies, Inc., an energy company, and Ikaria, Inc., a biotechnology company, acquired by Madison Dearborn Partners. Prior to joining ARCH, she was an associate with the Novartis BioVenture Fund in San Diego and an early employee at the Genomics Institute of the Novartis Research Foundation. Kristina received a B.A. in chemistry from the University of California, Berkeley, an M.A. in chemistry from Columbia University, and an MBA from the University of Chicago.
Robert has served as a member of our board of directors since January 2015. Since 2010, he has served as Managing Partner at venBio Partners LLC, a life sciences investment firm, which he co-founded in 2009. Prior to co-founding venBio, Robert worked at OrbiMed Advisors LLC from 2002 to 2008, where he led numerous investments in both private and public companies across three venture capital funds. In addition, he previously served on the boards of Apellis Pharmaceuticals, Inc., Seragon and Aragon. Robert received his B.A. from University of California, Berkeley and his M.D. from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey.
Richard, one of our co-founders, joined our board in September 2014 and has served as our Chairman since June 2015. From August 2013 to April 2015, he served as the Chief Executive Officer of Seragon, which he also co-founded. Prior to joining Seragon, Richard served as the Chief Executive Officer of Aragon, which he co-founded in 2009. Richard has served as Chairman of the Board of Directors of ORIC Pharmaceuticals, Inc., a private company focused on the discovery and development of novel therapies for treatment-resistant cancers, since November 2014. He serves as Vice Chair of the Board of Trustees of The Salk, and is a board member of Gritstone Oncology, Inc., Yumanity Therapeutics Inc., Vividion Therapeutics, Inc., and Mavupharma Inc. Richard also serves on the Executive Committee of the Board of Visitors at the UCSD Moores Cancer Center. He received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.